Virtual Library
Start Your Search
P. Li
Author of
-
+
P3.01 - Advanced NSCLC (ID 621)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.01-061 - Endostar Combined with Re-Challenged Gefitinib in Previous Treatment Failed NSCLC: A Retrospective Study (ID 9950)
09:30 - 09:30 | Author(s): P. Li
- Abstract
Background:
To investigate the efficacy of gefitinib combined with recombinant human endostatin (endostar) as a salvage therapy in patients who failure to benefit from gefitinib in previous treatment of advanced non‐small cell lung cancer (NSCLC) due to resistance with T790M mutant negative or unknown.
Method:
Patients with pathologically confirmed stage IV NSCLC who had failed of disease control by gefitinib were retrospectively reviewed. In total, twenty patients were enrolled incluing two patients with squamous disease, eighteen patients were adenocarcinoma. The median age was 61.6, ranging from 43 to 75. After acquired gefitnib treatment resistance, six patients were tested their tumor samples by re‐biopsy and confirmed T790M negative. Fourteen patients refused to re-biopsy, therefore the T790M status were unknow among them. In our analysis, from September 2009 to May 2014, all patients met the selection standards above received endostar (15 mg/day, i.v. day 1‐7, 21 days per cycle) additionally and keep taking gefitinib after preious treatment failure. The efficacy and toxicities of the combined treatment were observed.
Result:
Two patient achieved partial response (PR) (10%) , twelve patients had stable disease (SD) (60%) , six of those patient had progressive disease (PD) (30%) . The objective response rate (ORR) was 10% and the disease control rate (DCR) was 70%. Median progression free survival was 4.2 months (95% CI, 3.21 ‐ 5.19 months) , whereas median OS time was 8.0 months (95% CI, 4.96 ‐ 11.04 months). The results of efficacy accessed in terms of DCR, PFS and OS were not correlated with the sex, age, performance status (PS) score, histologic types or the treatment duration of gefitinib.
Conclusion:
After the failed attempting of gefitnib treatment, the combination of Endostar with gefitinib treatment could stabilize disease in T790M negative or unknown patients, and prolonged their survival time with tolerable toxicities.
